On the date of our inception, we issued 2 million shares of our common stock to our three officers and directors which were recorded at no value (offsetting increases and decreases in common stock and additional paid-in capital).

Doc Pharma S.A.

As of March 31, 2021, the Company has a prepaid balance of $3,522,041 and an accounts payable balance of $27,453, resulting in a net prepaid balance of $3,494,588 to Doc Pharma S.A. related to purchases of inventory. Additionally, the Company has a receivable balance of $3,247,612. As of December 31, 2020, the Company has a prepaid balance of $3,468,653 to Doc Pharma S.A. related to purchases of inventory. Additionally, the Company had a receivable balance of $3,468,564.

During the three months ended March 31, 2021 and 2020, the Company purchased a total of $589,261 and $670,631 of products from Doc Pharma S.A., respectively. During the three months ended March 31, 2021 and 2020 the Company had $290,598 and $261,543 in revenue from Doc Pharma S.A., respectively.

Doc Pharma S.A is considered a related party to the Company due to the fact that the CEO of Doc Pharma is the wife of Grigorios Siokas, the Company’s CEO and principal shareholder, who also served as a principal of Doc Pharma S.A. in the past.

Notes Payable – Related Party

A summary of the Company’s related party notes payable as of March 31, 2021 and December 31, 2020 is presented below:

	2021			2020

Beginning Balance	$	501,675		$	1,375,532
Payments		-			(996,136	)
Foreign currency translation		(19,977	)		122,279
Ending Balance	$	481,698		$	501,675

Grigorios Siokas

On December 20, 2018, the €1,500,000 ($1,718,400) note payable, originally borrowed pursuant to a Loan Agreement with a third-party lender, dated March 16, 2018, was transferred to Grigorios Siokas. The note bears an interest rate of 4.7% per annum and matured on March 18, 2019 pursuant to the original agreement. The note is not in default and the maturity date has been extended until December 31, 2021. As of December 31, 2020, the note had an outstanding principal balance of €400,000 ($489,200) and accrued interest of €158,287 ($193,585). As of March 31, 2021, the Company has an outstanding balance of €400,000 ($469,720) and accrued interest of €198,220 ($232,770).

Grigorios Siokas is the Company’s CEO and principal shareholder.

Dimitrios Goulielmos

On November 21, 2014, the Company entered into an agreement with Dimitrios Goulielmos, as amended on November 4, 2016. Pursuant to the amendment, this loan has no maturity date and is non-interest bearing. As of December 31, 2020, the Company had a principal balance of €10,200 ($12,475). As March 31, 2021 a principal balance of €10,200 ($11,978) remained as of March 31, 2021.

Dimitrios Goulielmos is a current director and former CEO of the Company.

The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2021 the Company recorded a loss of $19,977.

Loans Payable – Related Party

A summary of the Company’s related party loans payable during the three months ended March 31, 2021, and the year ended December 31, 2020 is presented below:

	2021			2020

Beginning Balance	$	1,629,246		$	1,026,264
Proceeds		398,864			725,563
Payments		(65,761	)		(149,695	)
Foreign currency translation		(20,577	)		27,114
Ending Balance	$	1,941,773		$	1,629,246

Grigorios Siokas

From time to time, Grigorios Siokas loans the Company funds in the form of non-interest bearing, no-term loans. As of December 31, 2020, the Company had an outstanding principal balance under these loans of $1,629,246 in loans payable to Grigorios Siokas. During the three months ended March 31, 2021, the Company borrowed additional proceeds of €169,000 ($198,865) and $200,000 and repaid €56,000 ($65,761) of these loans. As of March 31, 2021, the Company had an outstanding balance under these loans of $1,941,773.

The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2021 the Company recorded a loss of $20,577.

Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons.